首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1897784

疫苗佐剂市场规模、份额和成长分析（按产品、佐剂类型、给药途径、疾病类型、应用、疫苗类型和地区划分）－2026-2033年产业预测

Vaccine Adjuvants Market Size, Share, and Growth Analysis, By Product (Emulsion Adjuvants, Pathogen Components), By Adjuvant Type, By Route Of Administration, By Disease Type, By Application, By Vaccine Type, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球疫苗佐剂市场规模将达到 7.1171 亿美元，从 2025 年的 7.5591 亿美元成长到 2033 年的 12.2403 亿美元，在预测期（2026-2033 年）内，复合年增长率为 6.21%。

由于新发和再发病原体引发的感染疾病日益猖獗，全球疫苗佐剂市场正经历显着成长。感染疾病的激增凸显了疫苗接种的重要性，进而导致对增强免疫效力的佐剂的需求不断增长。佐剂是建构强大感染疾病防御机制的关键要素，它透过延长注射部位抗原的持续时间和调节免疫反应来增强疫苗效力。近期健康危机引发的全球医疗保健转型进一步凸显了疫苗接种策略的价值。此外，研发领域的持续进步催生了许多创新疫苗候选产品，为佐剂（疫苗效力最大化的关键成分）拓展了市场机会。

全球疫苗佐剂市场驱动因素

受新冠肺炎疫情的严重影响，全球健康问题日益严峻，导致疫苗需求激增，尤其是使用佐剂的疫苗。这种对疫苗接种策略的日益重视旨在有效对抗各种感染疾病和新出现的病原体，并维持群体免疫。为此，疫苗生产产业正积极寻求创新解决方案，透过投资先进的佐剂技术来提高疫苗效力。这项持续的努力不仅应对了当前的健康挑战，也加强了公共卫生防御，抵御未来的威胁，从而推动了全球疫苗佐剂市场的成长。

限制全球疫苗佐剂市场的因素

全球疫苗佐剂市场面临许多限制因素，其中最主要的限制因素是严格的监管壁垒，这些壁垒限制了产品的上市审批流程。这些严格的要求可能会延缓新佐剂的上市，最终影响其市场进入时间。此外，日益严格的监管环境推高了生产成本，增加了企业的财务负担，可能阻碍市场成长。遵守复杂的法规结构需要投入大量资源，这对寻求开发和推出新产品的中小企业尤其具有挑战性。在竞争激烈的市场环境中，确保符合安全法规也带来了额外的挑战。

全球疫苗佐剂市场趋势

全球疫苗佐剂市场正呈现出对个人化疫苗接种方案显着发展的趋势，该方案着重于根据每位患者独特的基因和免疫特征量身定制疫苗。这种创新方法旨在透过使用针对特定免疫需求的客製化佐剂来提高疫苗效力和改善患者预后。从「一刀切」模式转向更具针对性的策略转变，有望推动市场取得重大进展，并刺激对先进佐剂技术的需求。这一发展不仅有望提高疫苗接种的整体有效性，还有助于提高患者在接种过程中的参与和依从性。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

GSK plc（UK）
SEPPIC（France）
Croda International Plc（UK）
SPI Pharma（USA）
Agenus Inc.（USA）
Phibro Animal Health Corporation（USA）
Aurorium（USA）
Dynavax Technologies Corporation（USA）
Novavax Inc.（USA）
Merck KGaA（Germany）
Vaxine Pty Ltd.（Australia）
Hawaii Biotech Inc.（USA）
CSL Limited（Australia）
OZ Biosciences（France）
InvivoGen（USA）
Allergy Therapeutics（UK）
EuBiologics Co., Ltd.（South Korea）
Pacific GeneTech Limited（USA）
Riboxx GmbH（Germany）
Oncovir, Inc.（USA）

结论与建议

简介目录

Product Code: SQMIG35I2155

Global Vaccine Adjuvants Market size was valued at USD 711.71 Million in 2024 and is poised to grow from USD 755.91 Million in 2025 to USD 1224.03 Million by 2033, growing at a CAGR of 6.21% during the forecast period (2026-2033).

The global vaccine adjuvants market is experiencing significant growth driven by the rising prevalence of infectious diseases caused by both emerging and re-emerging pathogens. This surge in infectious diseases heightens the importance of vaccinations, leading to a greater demand for adjuvants that enhance immunization effectiveness. As a critical factor in developing robust defenses against infections, adjuvants boost vaccine potency by prolonging antigen presence at injection sites and modulating immune responses. The global shift towards preventive healthcare, influenced by recent health crises, further emphasizes the value of vaccination strategies. Additionally, ongoing advancements in research and development are yielding a broader array of innovative vaccine candidates, thereby expanding the market opportunities for adjuvants, which are essential for maximizing vaccine efficacy.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccine Adjuvants market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccine Adjuvants Market Segments Analysis

Global Vaccine Adjuvants Market is segmented by Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type and region. Based on Product, the market is segmented into Emulsion Adjuvants, Pathogen Components, Saponin-Based Adjuvants, Particulate-Based Adjuvants and Other Adjuvants. Based on Adjuvant Type, the market is segmented into Organic Adjuvants and Inorganic Adjuvants. Based on Route Of Administration, the market is segmented into Intramuscular, Subcutaneous and Other Routes of Administration. Based on Disease Type, the market is segmented into Infectious Diseases, Cancer and Other Diseases. Based on Application, the market is segmented into Research Applications and Commercial Applications. Based on Vaccine Type, the market is segmented into Human Vaccines, Veterinary Vaccines and Other Animals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vaccine Adjuvants Market

The surge in global health concerns, significantly influenced by the COVID-19 pandemic, has led to an intensified demand for vaccinations, particularly those utilizing adjuvants. This heightened focus on immunization strategies aims to effectively combat diverse infectious diseases and emerging pathogens, thereby ensuring community immunity is maintained. In response, the vaccine manufacturing sector is actively pursuing innovative solutions to enhance the efficacy of vaccines by investing in advanced adjuvant technologies. This ongoing pursuit not only addresses immediate health challenges but also fortifies public health defenses against future threats, driving the growth of the global vaccine adjuvants market.

Restraints in the Global Vaccine Adjuvants Market

The global Vaccine Adjuvants market faces significant constraints due to stringent regulatory barriers that govern the licensing process. These rigorous requirements can lead to delays in the introduction of new adjuvants, ultimately impacting the timeline for market entry. Furthermore, the heightened regulatory landscape can increase manufacturing costs, creating additional financial burdens that may stifle market growth. Navigating the complex regulatory framework demands considerable resources, posing challenges for companies, particularly smaller businesses, that aspire to innovate and introduce new products. Ensuring compliance with safety regulations adds another layer of difficulty in an already competitive market environment.

Market Trends of the Global Vaccine Adjuvants Market

The Global Vaccine Adjuvants market is experiencing a notable trend towards personalized immunization plans, where the focus is on tailoring vaccines to the unique genetic and immune profiles of individual patients. This innovative approach aims to enhance vaccine efficacy and patient outcomes by utilizing custom-designed adjuvants that cater to specific immunological needs. By shifting from a one-size-fits-all model to more targeted strategies, the market is poised for significant advancements, driving demand for sophisticated adjuvant technologies. This evolution not only promises to improve the overall effectiveness of vaccinations but also enhances patient engagement and compliance in the immunization process.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Patent Analysis

Global Vaccine Adjuvants Market Size by Product & CAGR (2026-2033)

Market Overview
Emulsion Adjuvants
Saponin-Based Adjuvants
Particulate-Based Adjuvants
Other Adjuvants

Global Vaccine Adjuvants Market Size by Adjuvant Type & CAGR (2026-2033)

Market Overview
Organic Adjuvants
Inorganic Adjuvants
Global Vaccine Adjuvants Market Size by Route Of Administration & CAGR (2026-2033)
Market Overview
Intramuscular
Subcutaneous
Other Routes of Administration

Global Vaccine Adjuvants Market Size by Disease Type & CAGR (2026-2033)

Market Overview
Infectious Diseases
Cancer
Other Diseases

Global Vaccine Adjuvants Market Size by Application & CAGR (2026-2033)

Market Overview
Research Applications
Commercial Applications

Global Vaccine Adjuvants Market Size by Vaccine Type & CAGR (2026-2033)

Market Overview
Human Vaccines
- Infectious Diseases
- Therapeutic
Veterinary Vaccines
- Companion Animals
- Livestock Animals
Other Animals

Global Vaccine Adjuvants Market Size & CAGR (2026-2033)

North America (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- US
- Canada
Europe (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

GSK plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SEPPIC (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Croda International Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SPI Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agenus Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Phibro Animal Health Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurorium (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dynavax Technologies Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxine Pty Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hawaii Biotech Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OZ Biosciences (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
InvivoGen (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergy Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EuBiologics Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pacific GeneTech Limited (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Riboxx GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oncovir, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments